ESTRO 2023 - Abstract Book

S1610

Digital Posters

ESTRO 2023

Prospectively enrolling 15 patients with LARC receiving pre-operative volumetric modulated arc therapy (VMAT) IGRT, both pre- and post-CBCT images from five treatment fractions per patient were acquired. The CTV, bowel loops and bladder were delineated on all images, with the exception of areas where air-artefacts forced the bowel loop contouring closer to a bowel bag structure, as seen in Figure 1. For IGRT, the ITV-to-PTV margins were 8 mm in all directions but ventrally where the expansion was 11 mm, according to clinical practice. For ART, the CTV was expanded with an isotropic PTV margin of 4 mm. Using the Ethos research software (the Emulator, Varian Medical systems, Inc.), online ART was simulated on the pre-CBCTs. Dose from the simulated IGRT and ART treatments were then overlaid on the six-degree bone-matched post-CBCT for dose evaluation in the Eclipse treatment planning system (Varian Medical systems, Inc.). The treatment was considered robust if average D99% to the CTV exceeded 95% on the post-CBCTs. The bowel volume receiving 7.5 Gy (V7.5 Gy ) and 20 Gy (V20 Gy) on the post-CBCTs were analysed, as both low and high dose levels can impact bowel toxicity. In addition, the mean dose to the bladder was analysed.

Results Analysis of the five first patients show a CTV coverage of D99% ≥ 97% in all treatment fractions, thereby all adapted plans were considered robust based on our criteria. On average, the PTV volume was reduced by 28% compared to the IGRT PTV volume, resulting in a reduction in both low and high dose to bowel (Figure 2). Patients with larger PTVs tended to benefit the most from the adaption. The average bowel dose reduction in V7.5 Gy and V20 Gy were both 29%, while mean dose to bladder was reduced by on average 3%.

Conclusion Robust online ART has the potential of sparing both low and high dose to the bowel, which is to be further verified on the rest of the cohort.

PO-1868 Quantifying movement of optical structures during radiotherapy treatment

D. Hofstede 1 , F. Vaassen 2 , C.M. Zegers 1 , N. Birimac 3 , I. Compter 1 , W. van Elmpt 1 , D.B. Eekers 1

1 Maastricht University Medical Center+, GROW School for Developmental Biology and Oncology, Department of Radiation Oncology (Maastro), Maastricht, The Netherlands; 2 Maastricht University Medical Center+, GROW School for Developmental Biology and Oncology, Department of Radiation Oncology (Maastro), Maastricht , The Netherlands; 3 Maastricht University